Avoro Capital Advisors LLC Ascendis Pharma A/S Transaction History

Avoro Capital Advisors LLC

$6.86 Billion
Q4 2024

A detailed history of Avoro Capital Advisors LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Avoro Capital Advisors LLC holds 5,103,055 shares of ASND stock, worth $789 Million. This represents 10.24% of its overall portfolio holdings.

Number of Shares

5,103,055

Previous 4,988,888 2.29%

Holding current value

$789 Million

Previous $745 Million 5.7%

% of portfolio

10.24%

Previous 11.21%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $13.9 Million - $16.7 Million	114,167 Added 2.29%	5,103,055 $703 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $89.5 Million - $122 Million	792,227 Added 18.88%	4,988,888 $745 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $27.8 Million - $35.3 Million	229,995 Added 5.8%	4,196,661 $572 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $26.1 Million - $33.7 Million	211,111 Added 5.62%	3,966,666 $600 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $7.37 Million - $10.9 Million	85,555 Added 2.33%	3,755,555 $473 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $7.74 Million - $9.3 Million	89,445 Added 2.5%	3,670,000 $344 Million
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $17.9 Million - $25 Million	255,555 Added 7.69%	3,580,555 $320 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $23.6 Million - $28.5 Million	225,000 Added 7.26%	3,325,000 $357 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $24.9 Million - $33 Million	250,000 Added 8.77%	3,100,000 $379 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $48.3 Million - $63.4 Million	575,000 Added 25.27%	2,850,000 $294 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $5.86 Million - $8.82 Million	75,000 Added 3.41%	2,275,000 $211 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $20.4 Million - $27.2 Million	200,000 Added 10.0%	2,200,000 $258 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $2.54 Million - $3.39 Million	20,000 Added 1.01%	2,000,000 $269 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $9.01 Million - $14.2 Million	80,000 Added 4.21%	1,980,000 $316 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $231 Million - $276 Million	1,900,000 New	1,900,000 $250 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $225 Million - $312 Million	-1,800,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $6.71 Million - $7.72 Million	50,000 Added 2.86%	1,800,000 $278 Million
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $4.1 Million - $5.77 Million	-37,000 Reduced 2.07%	1,750,000 $259 Million
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $7.57 Million - $11.3 Million	-78,000 Reduced 4.18%	1,787,000 $201 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $9.6 Million - $14.6 Million	-105,000 Reduced 5.33%	1,865,000 $259 Million
Q2 2019 Aug 14, 2019	BUY	$107.11 - $132.09 $18.7 Million - $23.1 Million	175,000 Added 9.75%	1,970,000 $227 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $11.5 Million - $24 Million	-185,000 Reduced 9.34%	1,795,000 $211 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $919,186 - $1.16 Million	16,664 Added 0.85%	1,980,000 $124 Million
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $6.38 Million - $7.63 Million	-100,000 Reduced 4.85%	1,963,336 $139 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $14.9 Million - $26 Million	382,312 Added 22.74%	2,063,336 $135 Million
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $1.44 Million - $1.81 Million	44,900 Added 2.74%	1,681,024 $67.3 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $44 Million - $60.7 Million	1,636,124	1,636,124 $59.3 Million

Others Institutions Holding ASND

# of Institutions

236

Shares Held

60.2M

Call Options Held

80.3K

Put Options Held

216K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.63B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.

Account

Avoro Capital Advisors LLC Ascendis Pharma A/S Transaction History